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Background: The redox activity of Ref-1 
activates the binding of several transcription 
factors important in cancer. 
Results: Repression of Ref-1 potently activates 
NRF2 resulting in upregulation of target gene 
expression. 
Conclusion: Activation of NRF2 is a potential 
mechanism of resistance to therapies based on 
Ref-1 inhibition. 
Significance: Dual blockade of Ref-1 and NRF2 
or specific downstream target, HMOX-1, 
represents a strategy for overcoming resistance. 
 
ABSTRACT 
Apurinic/Apyrimidinic 
endonuclease/Redox factor-1 (APE1/Ref-1) 
(henceforth referred to as Ref-1) is a multi-
functional protein that in addition to its 
base-excision DNA repair activity exerts 
redox control of multiple transcription 
factors, including nuclear factor kappa-light-
chain-enhancer of activated B cells (NF-κB), 
STAT3, activator protein-1 (AP-1), hypoxia-
inducible factor-1 (HIF-)1 and tumor protein 
53 (p53). In recent years, Ref-1 has emerged 
as a promising therapeutic target in cancer, 
particularly in pancreatic ductal carcinoma 
(PDAC). While a significant amount of 
research has centered on Ref-1, no wide-
ranging approach had been performed on the 
effects of Ref-1 inhibition and transcription 
factor activity perturbation. Starting with a 
broader approach, we identified a previously 
unsuspected effect on the Nuclear factor-
erythroid-related factor 2 (NRF2), a critical 
regulator of cellular defenses against 
oxidative stress. Based on genetic and small 
molecule inhibitor-based methodologies, we 
demonstrated that repression of Ref-1 
potently activates NRF2 and its downstream 
targets in a dose-dependent fashion, and that 
the redox, rather than the DNA repair 
function of Ref-1 is critical for this effect. 
Intriguingly, our results also indicate that this 
pathway does not involve Reactive Oxygen 
Species (ROS). The link between Ref-1 and 
NRF2 appears to be present in all cells tested 
in vitro, noncancerous and cancerous, 
including patient-derived tumor samples. In 
particular, we focused on understanding the 
implications of the novel interaction between 
these two pathways in primary PDAC tumor 
cells and provide the first evidence that this 
mechanism has implications for overcoming 
the resistance against experimental drugs 
targeting Ref-1 activity, with clear 
translational implications. 
Redox factor-1 (Ref-1) is a dual function 
protein which in addition to DNA repair 
function controls the activity of multiple 
transcription factors (TFs), including NF-kB 
(nuclear factor-kB), STAT3, AP-1 (activator 
protein-1), HIF-1 (hypoxia inducible factor) (1-
4). The redox activity of Ref-1 reduces specific 
cysteine residues in the DNA binding domain of 
these TFs, thus stimulating their DNA binding 
activity (5). As most transcription factors 
stimulated by Ref-1 are well recognized 
regulators of tumorigenesis, this protein has 
emerged as a viable therapeutic target in cancer 
(3,5-7). Particular attention has been given to 
pancreatic ductal adenocarcinoma (PDAC) as 
Ref-1 levels are known to be elevated in a 
variety of human PDAC-derived cell lines as 
well as in neoplastic tissue and peri-pancreatic 
metastases. We and others demonstrated that 
silencing Ref-1 in pancreatic cancer cells 
resulted in apoptosis and decreased proliferative 
capacity (8,9). Furthermore, blockade of Ref-1 
redox activity delayed tumor progression in 
xenograft models of human PDAC, including 
patient-derived tumor cells (4).  
However much remains to be elucidated 
about Ref-1’s functions, particularly with 
respect to the biochemical consequences of its 
inhibition. Detailed knowledge at this level is 
anticipated to increase the effectiveness of Ref-1 
inhibitors and help delay/overcome therapeutic 
resistance to such agents. To this end, we 
performed a comprehensive survey of the effects 
of Ref-1 inhibition on the activity of a broad 
spectrum of transcription factors, using a library 
of reporters (Attagene, Inc)(10). Our approach 
led to a novel connection between Ref-1 and 
Nuclear factor-erythroid-related factor 2 
(NRF2), a critical regulator of cellular defenses 
against oxidative stress (11).  
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MATERIALS AND METHODS 
Cell lines and patient-derived PDAC cells.  
MIA-PaCa-2 were purchased from and 
authenticated by ATCC (Manassas, VA). 
Pa03C, Panc10.05, Panc 198, and Pa02C were 
obtained from Dr. Anirban Maitra at The Johns 
Hopkins University.(12) All cells were 
maintained at 37°C in 5% CO2 and grown in 
DMEM (Invitrogen; Carlsbad, CA) with 10% 
FBS (Hyclone; Logan, UT) and routinely tested 
for mycoplasma. 
Inhibitors. E3330 and RN7-58 were 
synthesized as previously described (13-15), and 
tin porphyrin (Sn-PP) was purchased from 
Sigma Aldrich. As a negative control, the E3330 
analog, RN7-58 was used. RN7-58, although 
structurally similar to E3330, does not inhibit 
Ref-1’s redox activity (16).  
Transfection of PDAC cells with siRNA.  
All siRNA transfections (Ref-1 (referred to as 
siRef-1#1) or scrambled control) were 
performed as previously described (3,13,17-19). 
Samples for the Attagene screen and quantitative 
PCR (QPCR) were collected 72 h after 
transfection of cancer cells with Ref-1 siRNA. 
For additional Ref-1 siRNA experiments, we 
purchased prevalidated siRNAs from LifeTech 
(#s1446, siRef-1#2, and s1447, siRef-1#3). 
Attagene cis-FACTORIAL screen. Our 
initial screen  for the effects of Ref-1 on the 
activity of a diverse panel of transcription 
factors was performed using Attagene’s cis-
FACTORIAL technology followed by validation 
of the NRF2 pathway using the relevant reporter 
from the library (10). PaCa-2 cells were 
transfected with siRef-1 or scrambled siRNA as 
above. Twenty-four hours later cells were 
washed with fresh medium and transiently 
transfected with cis-FACTORIALTM. Twenty-
four hours after transfection cells were supplied 
with fresh medium (containing 10% FBS) and 
incubated for an additional 24 h. Profiles of the 
FACTORIALTM endpoint activities were 
determined as fold-induction values of siRef-1 
or scrambled RNA transfected cells divided by 
values from untransfected cells. The 
methodology is described in detail in (10,20,21). 
QPCR Reactions. This method was used 
to measure the mRNA expression levels of 
NRF2 and its downstream target genes, HMOX-
1 (heme oxidase-1), GCLC (glutamate-cysteine 
ligase, catalytic subunit), and GCLM 
(glutamate-cysteine ligase, modifier subunit). 
Total RNA was extracted from cells using the 
Qiagen RNeasy Mini kit (Valencia, CA) 
according to the manufacturer's instructions. The 
extracted RNA was quantified using a Qubit 
fluorometer (Invitrogen Corp, Carlsbad, CA). 
First-strand cDNA was prepared from RNA 
using random hexamers and MultiScribe reverse 
transcriptase (Applied Biosystems, Foster City, 
CA). Quantitative PCR was performed using 
Taqman Gene Expression assays and Universal 
PCR master mix (Applied Biosystems) in a 
7900HT Sequence detection system (Applied 
Biosystems). The relative quantitative mRNA 
level was determined using the comparative Ct 
method using Actin (PaCa-2) or large ribosomal 
protein, P0 (RPLP0, patient lines) as the 
reference gene (4). The primers for NRF2, 
HMOX-1, GCLC, GCLM, Actin, and RPLP0 
are commercially available (Applied 
Biosystems). Experiments were performed in 
triplicate for each sample.  
Western blot analysis. Whole cell 
lysates were prepared by lysing the cells in 
RIPA buffer (Santa Cruz Biotechnology; Santa 
Cruz, CA), followed by quantification of protein 
concentration (Lowry protein assay). Proteins 
were separated by SDS-PAGE, electroblotted 
onto nitrocellulose, and immunoblotting was 
performed using the following antibodies: Ref-1 
and NRF2 (abcam 62352), HMOX-1 (Abcam, 
Cambridge, MA), and Ku70, tubulin or Actin 
(Sigma Aldrich). 
Reactive oxygen species (ROS) 
Measurement. The production of ROS was 
determined by detecting the fluorescent intensity 
of the oxidation-sensitive probe 
dihydrorhodamine 123 (DHR) (Molecular 
Probes, Invitrogen, Carlsbad, CA). PaCa-2 and 
Pa03C cells were treated with E3330 for 24 h. 
As a positive control for ROS production, tert-
Butyl hydroperoxide solution (TBHP, 1 mM, 30 
min) was utilized. After washing with PBS, the 
cells were incubated with 1 µM DHR in fresh 
PBS for 30 min. Excessive probe was washed 
off using PBS. Cells were harvested with trypsin, 
and ROS fluorescence of labeled cells was 
measured by using a Coulter EPICS XL flow 
cytometer (Coulter). An average of 10,000 cells 
from each sample was counted, and each 
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experiment was done in triplicate. 
Co-immunoprecipitation (Co-IP) 
Samples were co-immunoprecipitated using the 
Pierce Co-IP kit (Thermo Scientific) with the 
following modifications. Cells were washed 
twice with ice-cold PBS and the proteins were 
cross-linked using the water soluble, membrane 
permeable, imidoester crosslinker - dimethyl 
3,3’-dithiobispropiominidate (DTBP (Thermo 
Scientific), 5 mM, for 30 min on ice). DTBP 
was quenched by sequential washing with cold 
inactivation buffer (100 mM Tris HCl pH 8, 150 
mM NaCl) and PBS. Cells were lysed by the 
addition of IP Lysis buffer supplemented with 
protease inhibitors (800 µl per 10 cm dish; 4ºC, 
20 min on rocking platform) and then scraped 
and transferred to a microcentrifuge tube. Cell 
debris was removed by centrifugation and the 
protein concentration of the cleared lysate was 
determined using the Pierce BCA Protein assay. 
To reduce non-specific protein binding, 1.4 mg 
of cell lysate was pre-cleared using the control 
Agarose resin, prior to adding to columns of 
either Ref-1 or NRF2 antibody or control rabbit 
IgG that had been covalently coupled onto an 
amine-reactive Agarose resin. After extensive 
washing, the bound proteins were eluted and 
prepared for SDS-PAGE analysis by the 
addition of 5x sample buffer containing 100 mM 
DTT. 
ChIP assay. We performed ChIP assay 
according to the manufacturer’s protocol 
(Millipore). PaCa-2 cells were incubated for 16 
h in the presence of 67.5 µM E3330, or 0.17% 
DMSO in DMEM with 2% FBS. Proteins were 
crosslinked to DNA by the addition of 37% 
formaldehyde (to a final concentration of 1%, 10 
min, room temperature) and then quenched by 
adding glycine (125 mM, 5 min, room 
temperature). Cell lysates were sonicated (Sonic 
Dismembrator Model 100 (Fisher) setting #4, 12 
cycles, 10 sec) until cross-linked DNA was 
sheared to achieve lengths of 200 – 600 bp. The 
antibodies used were Ref-1(2ug), NRF2 (3ug), 
or control rabbit IgG (Cell Signaling). PCR 
primer sequences used are in Table 1. 
Transient Luciferase Reporter Assays. 
In order to generate an NRF2 activity reporter, 
we inserted into the pGL4 backbone vector the 
following sequence which corresponds to the 
NAD(P)H:quinone oxidoreductase antioxidant 
response element (ARE) (underlined): CCG 
CTC GAG AAA TCG CAG TCA CAG TGA 
CTC AGC AGA ATC TGA GCC TGG GCT 
ATA AAA GGG GGT GGG GGC GCG TTC 
GTC CTC AAG CTT GGG. Bases in italics 
indicate the minimal TATA-like sequences (10). 
PaCa-2 and Pa02C cells were co-transfected 
with the reporter construct and a Renilla 
luciferase control, pRL-TK (Promega Corp., 
Madison, WI), in a 20:1 ratio by using 
Lipofectamine 2000 (Invitrogen Life 
Technologies, Carlsbad, CA). Sixteen hours 
after transfection, cells were treated with E3330 
in 2-5% serum-containing media for 24 h, 
followed by assay for Firefly and Renilla 
luciferase activity using the Dual Luciferase 
Reporter Assay System (Promega Corp.) Each 
time, a medium-only control was included, and 
the final data is expressed as the fold change of 
the relative luciferase units compared to the 
vehicle control. DMSO concentration was 
equivalent in all samples and the final 
concentration was less than 0.25%.  All of the 
transfection experiments were performed in 
triplicate and repeated at least 3 times in 
independent experiments. 
Proliferation studies. The proliferative 
capacity of PDAC cells was assessed using the 
MTS assay as previously described (4). Cells 
were treated with varying doses of either E3330, 
or tin protoporphyrin, alone, or in combination 
with either hypoxia exposure (0.2% O2, Ruskinn 
InVivo200 hypoxia workstation) or low glucose 
containing medium for 48 h. 
 Tumors for HMOX-1 IHC. The tumors 
in this study had been maintained as a live 
PancXenoBank(4,12). Female nu/nu athymic 
mice (Harlan) were treated with either vehicle 
control or E3330, administered twice daily, 8 
hours apart, at 25 mg/kg for a total of 20 doses 
(5 days on 2 days off, 5 days on and 2 days off 
schedule) as previously described (4). At the end 
of this regimen, we collected tumor samples for 
immunostaining. 
 Statistical Analysis. All QPCR data 
points for vehicle, E3330, and RN7-58 
treatments were analyzed using the  2−∆∆𝐶𝐶𝑇𝑇  
method and analysis of covariance (ANCOVA) 
models (22). Specifically, for each target gene 
(HMOX-1, GCLC, GCLM) and each dose of 
Ref-1 inhibitor (25, 35, 50µM E3330) or 
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negative control, RN7-58 (RN25, RN35, RN50), 
an ANCOVA model using threshold cycle 
number, 𝐶𝐶𝑇𝑇 ,  of both treatment and vehicle 
control (DMSO) for both the target gene and the 
reference gene (Actin, or RPLP0, for 
normalization) were used as the response 
variable in the ANCOVA model. Covariates 
including group (treatment or control), target 
(target or reference gene), and their interaction 
were adjusted. If multiple experiments were 
conducted on different days, days were adjusted. 
The coefficient of the interaction terms in 
ANCOVA model is the estimate of the ∆∆Ct 
which is the difference of normalized target gene 
𝐶𝐶𝑇𝑇 between treatment and control sample, e.g., 
( 𝐶𝐶𝑇𝑇,HMOX−1(E25)−𝐶𝐶𝑇𝑇,RPLP0(E25))−(𝐶𝐶𝑇𝑇,HMOX−1(DMSO)−𝐶𝐶𝑇𝑇,RPLP0(DMSO)) . The 95% 
confidence interval of ∆∆Ct and p-value was 
also estimated based on ANCOVA model. The 
∆∆Ct estimates and the bounds of 95% 
confidence interval were transformed to 2-∆∆Ct 
value as the folds of change estimate and its 
confidence interval. Differences between the 
treatment group and control group were 
considered significant if p<0.05. All Statistical 
analyses were performed using SAS (Version 
9.3, SAS Institute Inc. Cary, NC). 
 
RESULTS 
Knockdown of Ref-1 increases NRF2 
activity and expression of NRF2 target, HMOX-
1. Using Attagene’s cis-FACTORIAL assay (10) 
to screen for activity of >50 transcription 
factors, following Ref-1 knockdown we 
observed changes in previously reported Ref-1 
targets such as AP-1 (data not shown). 
Unexpectedly, the most robust change in 
response to blockade of Ref-1 blockade was the 
induction of NRF2 (NFE2L2) activity. When 
Ref-1 protein levels were knocked down by 
more than 85%, NRF2 activity was increased 
3.5-fold compared to Scrambled (SCR) control 
in PaCa-2 cells (Figure 1A). In contrast, the 
impact of Ref-1 knockdown on NRF1 activity 
was minimal (1.3-fold, Figure 1A). To ensure 
this was not a cell specific observation, we 
expanded these findings in PaCa-2 cells to 
patient derived pancreatic cancer cells as well as 
a cancer-associated fibroblast (CAF) line. As 
shown in Figure 1B, the knockdown of Ref-1 
was effective in all cell lines tested. The effect 
of Ref-1 knockdown on the well-recognized 
NRF2 target, HMOX-1 (heme oxygenase-1) was 
assessed using QPCR and immunoblotting. In 4 
out of the 6 lines tested, decreased expression of 
Ref-1 corresponds to a statistically significant 
and generally robust increase in HMOX-1 as 
shown by QPCR (2 – 6 fold, Figure 1C, 95% 
confidence interval of ∆∆Ct and p-value based 
on ANCOVA model). To demonstrate that this 
effect is dependent upon Ref-1, patient-derived 
Pa03C cells were treated with increasing 
amounts of Ref-1 siRNA#1 (2 – 25nM). On day 
3 following transfection, we observed a dose-
dependent increase in HMOX-1 protein as Ref-1 
protein levels decrease (Figure 1D). This was 
confirmed with two additional siRNAs against 
Ref-1, which also led to significant increases of 
HMOX-1 levels (Figure 1E).   
Inhibition of Ref-1 using E3330 
activates NRF2 transcriptional activity. To more 
specifically address the role of the redox 
function of Ref-1 on NRF2 transcriptional 
activity, we generated a luciferase construct with 
an ARE sequence known to be activated by 
NRF2 (23).  
As the siRNA-based approach removes 
both redox and DNA repair functions of Ref-1, 
as well as any protein-protein interactions 
involving this protein, we used the small 
molecule, E3330, that directly inhibits Ref-1’s 
redox function without affecting its well-
documented endonuclease activity(14,24-26). In 
both PaCa-2 and low passage patient derived 
cells Pa02C, inhibition of Ref-1 with E3330 
markedly stimulates NRF2 activity in a dose-
dependent manner in transient luciferase assays 
(Figure 2, gray bars, p<0.05). Furthermore, 
treatment with E3330 analog, RN7-58 did not 
show significant stimulation of NRF2 activity in 
Pa02C cells (Figure 2B, white bars). RN7-58, 
although structurally similar to E3330, does not 
inhibit Ref-1’s redox activity (16) and serves as 
a negative control compound. To demonstrate 
that the Ref-1 protein is critical in the activation 
of NRF2 pathway and expression of HMOX-1, 
we knocked Ref-1 protein levels down using 
siRNA (Figure 2D) and then treated with E3330. 
As expected when Ref-1 protein is decreased in 
the absence of treatment, there is a 1.5-fold 
increase in HMOX-1 expression. When we treat 
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with E3330 PDAC cells that have a reduction in 
Ref-1 protein, we observe a comparable 
stimulation (1.8 fold) of HMOX-1 expression 
when normalizing for the increase observed with 
siRNA treatment (Figure 2C).  
To further consolidate the evidence for 
induction of NRF2 activity following inhibition 
of Ref-1, we quantitated the expression of three 
classic NRF2 target genes: GCLC, GCLM, and 
HMOX-1 in four patient-derived lines as well as 
PaCa-2 cells. Our results demonstrate a 
significant and dose-dependent increase in 
GCLC, GCLM, and HMOX-1 in all five cell 
lines (Figure 3, black bars, 95% confidence 
interval of ∆∆Ct and p-value based on 
ANCOVA model). The increase in gene 
expression for these three genes is abrogated 
when the negative control compound, RN7-58 is 
utilized (Figure 3, gray bars), again supporting a 
negative impact of Ref-1’s redox activity on 
NRF2.  
Inhibition of Ref-1 increases NRF2 at 
both RNA and protein levels. We next 
determined whether the elevated NRF2 activity 
in response to Ref-1 inhibition is caused by 
increased NRF2 expression. To this end, we 
analyzed RNA and protein levels of NRF2 in 
PaCa-2 cells as well as two patient-derived cell 
lines treated with E3330. There is a dose-
dependent increase of NRF2 in the levels of both 
RNA and protein by E3330 (Figure 4A). RN7-
58 failed to elicit such a response in all three cell 
lines tested (Figure 4A). A similar dose-
dependent response was also observed for the 
NRF2 target, HMOX-1 (Figure 4B).  
Inhibition of Ref-1did not increase ROS 
generation. Because NRF2 can be activated by 
various stressors including ROS (27-29), we 
next tested the effect of E3330 treatment on 
ROS production in pancreatic cancer cells 
(PaCa-2, Pa03C, Panc10.05, and Panc-1). ROS 
levels were quantified at various timepoints 
following increasing amounts of E3330, using 
the oxidant-sensitive probe dihydrorhodamine 
123 (DHR) analysis.  Although ROS levels 
dramatically increased with the positive control 
TBHP in all cell lines, at 24 – 48 h, we did not 
see increased ROS generation in the cell lines 
(Figure 5). Based on the data in Fig. 5, we 
conclude that the activation of NRF2 by E3330 
was independent of ROS generation. We have 
previously demonstrated that Ref-1 knockdown 
does not lead to detectable amounts of ROS 
therefore suggesting that ROS generation is not 
a significant contributor to the impact of Ref-1 
on NRF2 activity (8). 
Ref-1 and NRF2 co-immunoprecipitate. 
Based on the existing knowledge that Ref-1 
regulates the activity of several transcription 
factors by direct interaction, we also tested the 
possibility that Ref-1 and NRF2 can exist in the 
same protein complex. Indeed, we readily 
detected the presence of Ref-1 following 
immunoprecipitation of lysates with NRF2 
antibody (Figure 6A) and in reverse experiments 
the presence of NRF2 in the Ref-1 
immunoprecipates (Figure 6B). 
To test whether the interaction also 
occurs at sites where NRF2 exerts its 
transcription factor activity, ChIP was 
performed at specific sequences on the HMOX-
1 promoter.  These NRF2 binding sites were 
chosen based on published data showing these 
sites were bound by NRF2 (E1 and E2) (30) 
(Figure 7A). We also used the published MCM5 
site downstream of HMOX-1 as a negative 
control for non-specific chromatin binding. 
PaCa-2 were treated with E3330, RN7-58, 
vehicle control (7B, C) or Ref-1 siRNA #1, Ref-
1 pooled siRNA #2 and #3, or scrambled control 
(7D, E); followed by cross-linkage, chromatin 
fragmentation, and immunoprecipitation using 
anti-Ref-1, anti-NRF2 or IgG control antibodies. 
Recovered DNA was subjected to PCR using 
primers specific for NRF2 binding sites on 
HMOX-1 promoter. As presented in Figure 7B, 
NRF2 binding sequences on HMOX-1 promoter 
were co-precipitated by Ref-1 under control 
conditions, while treatment with E3330 
dramatically decreased the amount of DNA co-
precipitated with Ref-1. When chromatin IP was 
performed using the anti-NRF2 antibody we 
reproducibly detected increased recruitment of 
NRF2 at the same promoter sites following 
treatment with E3330, but not with negative 
control compound RN7-58 (Figure 7C), Finally, 
when Ref-1 was depleted using multiple siRNAs 
we observed a similarly increased NRF2 
recruitment to the HMOX-1 promoter versus 
scrambled control (Figure 7 D, E). In all cases, 
there is no binding to the negative control 
MCM5 site.  
6 
 
 at Indiana U
niversity School of M
edicine on July 1, 2015
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
  Ref-1 redox function negatively regulates NRF2 
 
To summarize, we provide the first 
evidence of a complex functional relationship 
between Ref-1 and NRF2 in PDAC cells.  On 
the one hand, inactivation of Ref-1 leads to 
increased levels of NRF2 transcript and protein. 
On the other hand, Ref-1 and NRF2 coexist in 
protein complexes, at least in part at defined 
promoter sites where NRF2 exerts its 
transcriptional activity. The evidence suggests 
that Ref-1 exerts inhibitory effects on this 
activity, potentially by direct redox regulation 
and independently of readily detectable ROS 
levels.  
Blockade of Ref-1 and HMOX-1 under 
hypoxic stress, but not glucose deprivation, 
results in synergistic effects on human PDAC 
cells. Targeting Ref-1 redox activity in PDAC 
exerts anti-tumor effects both in vitro and in vivo 
(4), and our data demonstrates that upon 
inhibition of Ref-1, NRF2 signaling is activated. 
Activation of NRF2 pathway has been 
previously associated with resistance to anti-
cancer drugs in PDAC and other cancers (31-
33). Based on this information and the data in 
Figure 3 demonstrating strong induction of 
HMOX-1 following Ref-1 inhibition, we 
hypothesized that targeting HMOX-1 in 
combination with Ref-1 would lead to 
sensitization of PDAC cells. Furthermore, 
combination treatment with Ref-1 redox 
inhibitor and HMOX-1 inhibitor may potentiate 
common stressors such as hypoxia and glucose 
deprivation in tumor cells as they adapt to low 
oxygen levels as well as a reduction in local 
glucose levels.  Based on our data demonstrating 
that inhibition of Ref-1 is activating NRF2 
signaling, we evaluated whether the combined 
blockade of HMOX-1 using Sn-PP (34) and of 
Ref-1 redox activity using E3330 synergizes to 
more effectively inhibit the growth of human 
PDAC cells. Cell survival was assessed using 
the MTS assay following 48 h of drug treatment. 
E3330 was used at doses that effectively inhibit 
Ref-1 redox activity, and HMOX-1 inhibitor at 
increasing doses. As single agents, dose-
dependent decreases in proliferation of PDAC 
cells was observed in the presence of Sn-PP 
(Figure 8A) or E3330 (Fig. 8B, (4)). We 
observed that Ref-1 redox inhibition by E3330 
synergizes with HMOX-1 blockade most 
dramatically under hypoxic stress condition, but 
not glucose deprivation (Fig. 8A, bottom panel). 
The effects were seen both in PaCa-2 cells, and 
primary patient-derived Pa03C cells (Fig. 8B).  
HMOX-1 protein is expressed in low 
passage patient-derived xenografts treated with 
Ref-1 inhibitor. For the immunohistology (IHC) 
studies, grafted patient tumors that had been 
maintained as a live PancXenoBank (12) were 
utilized as described in (4). Female nu/nu 
athymic mice (Harlan) treated with either 
vehicle control or E3330 at 25 mg/kg. At the end 
of this regimen, we collected tumor samples for 
immunostaining. This dose was effective at 
reducing tumor volume in previously published 
studies.(4) A total of seven vehicle-treated 
tumors and 15 E3330-treated tumors were 
evaluated for HMOX-1 immunostaining. 
Moderate cytoplasmic immunostaining is seen in 
the tumor cell epithelia in a majority of 
pancreatic adenocarcinoma cases 
examined.  There is significant higher staining 
intensity of HMOX-1 in patient tumors that were 
treated with E3330, versus vehicle-treated (* 
p<0.05). Elevated levels of HMOX-1 after Ref-1 
inhibition are consistent with our hypothesis that 
upregulation of NRF2 signaling may contribute 
to the resistance of pancreatic cancer to Ref-1 
inhibition.  
 
DISCUSSION 
Our study characterizes for the first time 
a novel functional interaction between the dual 
function protein, Ref-1 and NRF2, a regulator of 
cellular redox responses. While the pathways 
regulated by Ref-1 have been studied in detail 
for more than a decade, this is the first report of 
a negative interaction mediated by Ref-1. The 
available published information from initial 
studies suggesting a potential link, however 
implied a positive effect on NRF2, analogous to 
the effect on HIF, p53 and AP-1. (35)  
We determined that the repression of 
Ref-1 leads to activation NRF2 and its function 
in all the cell types tested, primary and 
transformed. The induction at least in part 
occurs at transcriptional level, as the blockade of 
transcription with actinomycin D abolished the 
effect (data not shown). The level of NRF2 
protein is induced in a dose dependent fashion, 
as is the level of multiple NRF2 targets, such as 
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HMOX-1 or enzymes involved in glutathione 
synthesis. 
Although activation of NRF2 pathway 
frequently involves an increased level of ROS, 
as in the case of treatment with sulforaphane 
(SFN) or tert-Butylhydroquinone (TBHQ) (36), 
we saw no evidence that ROS are generated in 
higher amounts following Ref-1 blockade. 
Based on the general response in all the 
cells tested, activation of NRF2 as a 
consequence of Ref-1 inactivation may represent 
a major shift in the ability of cells to cope with 
oxidative stress. This may have implications for 
the resistance to drug therapy that directly or 
indirectly inhibit Ref-1. 
To our knowledge the only study linking 
Ref-1 to NRF2 activity indicated a stimulatory 
effect on ferritin H gene transcription following 
Hemin treatment (35). The caveat is that the 
previous work was performed in one cell line 
(K562) rather than patient-derived tumor cells 
and in vivo tumors as described here.  
Employing multiple siRNAs, and small 
molecules we tested a panel of well-established 
NRF2 targets, as well as NRF2 transcript, 
protein levels, and direct activity in reporter 
assays. We certainly cannot exclude the 
possibility that the interplay between Ref-1 and 
NFR2 may lead to differential or even opposite 
effects for some NRF targets, in specific cellular 
contexts. However, our results indicate that the 
portrayal of Ref-1 as a general “helper” of 
specific transcription factors may need to be 
revisited. 
While our work does not dissect the 
biochemistry of Ref-1 – NRF2 relationship, it 
indicates at least two major mechanisms of 
repression, one being control of NRF2 mRNA 
level. In timely fashion, Ref-1 was recently 
reported to repress the expression of p21 gene 
(37), in association with the AP4 factor at 
specific sites within the p21 promoter. 
Interestingly, the NRF2 promoter contains two 
AP4 sites (not shown), which may mediate a 
similar repressive effect of Ref-1. 
Finally, our work anticipates novel 
strategies to improve the efficacy of 
experimental anti-cancer agents acting on Ref-1 
function. Among NRF2 targets, HMOX-1 is a 
candidate protumorigenic gene product and 
preclinical development of targeted small 
molecule inhibitors is being actively pursued 
(38). More importantly, HMOX-1 is emerging 
as important contributor to tumor cell resistance 
to chemotherapeutic agents, such as imatinib 
(39). In pancreatic cancer cells, gemcitabine or 
radiation strongly induced HMOX-1 expression 
and its knockdown was shown to inhibit growth 
while increasing radio- and chemo-sensitivity 
(40) (41). 
Our work predicts a mechanism of 
resistance to therapies based on Ref-1 inhibition 
and opens the road for development of 
synergizing strategies, dependent on the dual 
blockade of Ref-1 and NRF2 or specific 
downstream targets, such as HMOX-1. The 
main justification for focusing on the latter in 
the present work is the availability of small 
molecule inhibitors that could be tested in 
conjunction with pharmacological Ref-1 
blockade. Moreover, in pancreatic tumors 
treated with E3330, HMOX-1 is induced, 
conceivably as part of resistance.  
In vitro, Ref-1 redox inhibition appears 
to be synthetically lethal with HMOX-1 
blockade in particular under low oxygen 
conditions. Speculating future translational 
implications, such combinations may exhibit 
lower toxicity on (well-oxygenated) normal 
tissues and target in particular tumor cells 
surviving in hypoxic compartments, which 
represent important sources of therapeutic 
failure. 
We are aware of the limitations of 
porphyrin-based compounds, however, our 
investigation was intended to serve as proof of 
principle, in anticipation of newer generations of 
HMOX-1 inhibitors such as imidazole-dioxolane 
derivatives, currently under evaluation (42).  
Furthermore, it has been demonstrated 
that targeted inactivation of Ref-1 sensitizes 
cells in vitro to a variety of genotoxic agents, 
including antineoplastic agents: TMZ, BCNU, 
etoposide, cisplatin and doxorubicin (6,7,19,37). 
Our work suggests that these effects may be 
further enhanced by the concomitant blockade of 
NRF2 pathway or select targets such as HMOX-
1.  
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FIGURE LEGENDS 
 
FIGURE 1. Transcriptional Activity of NRF2 and NRF1 after Ref-1 knockdown in PaCa-2 cells. A) 
PaCa-2 cells were transfected on sequential days with siRef-1#1 and then cis-FACTORIALTM system. 
After an additional 24 h, NRF1 and NRF2 activities were determined as fold-induction values of 
scrambled or siRef-1 transfected cells divided by values from mock transfected cells. Data is shown as 
fold-induction values. *,p < 0.05 comparing siRef-1 versus scrambled control; n= 3. B) Immunoblotting 
for Ref-1 on Day 3 following transfection of 100nM siRNA; C) NRF2 target gene, HMOX-1 RNA levels 
are elevated in patient derived tumor cells and cancer-associated fibroblast line (CAF19) following 
knockdown of Ref-1 with si#1. HMOX-1 QPCR was performed on Day 3 following transfection of 
siRNA. D) Western blot for HMOX-1 protein levels in Pa03C cells following Ref-1 knockdown (Day 3) 
with increasing amount of siRNA#1; E) Western blot showing Ref-1 protein levels are decreased 
following transfections with Ref-1 siRNAs. qPCR for HMOX-1 levels following transfection of Ref-1 
siRNA #1, siRNA #2 (s1446) & siRNA #3 (s1447; 50nM, PaCa-2 Day 3 following transfection). *, p < 
0.05: **, p < 0.01 comparing siRef-1 versus scrambled control; n = 3-6. 
FIGURE 2. NRF2 activity is increased in a dose-dependent manner when Ref-1 redox activity is 
inhibited via E3330. Pancreatic cancer cells, PaCa-2 (A) and Pa02C (B) were assayed for NRF2 activity 
via luciferase reporter assay.  At 24 h post-transfection of luciferase and firefly constructs, PDAC cells 
were treated with vehicle control (DMSO), E3330, or negative control compound, RN7-58 for 24 h and 
then the luciferase assay was conducted. Doses were based on survival data from previously published 
data (4).  C) Quantitation of HMOX-1 expression by qPCR using PaCa-2 cells transfected with Ref-1 
siRNA#1 or scrambled control and then treated with E3330 at 50µM for 24 hr; and D) Immunoblot for 
Ref-1 for the samples in C with Actin as loading control.*, p < 0.05, comparing DMSO control to drug-
treated samples;  n = 3-4. 
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FIGURE 3. Inhibition of Ref-1 increases NRF2 activity in 4 patient-derived cells as well as 
established PDAC line, PaCa-2. Using three genes (HMOX-1, GCLC, and GCLM) as markers of NRF2 
activity, we quantitatively determined the impact of Ref-1 inhibition (black bars) on gene expression by 
QPCR. PaCa-2 and patient-derived lines were treated with increasing amounts of E3330 for 24 h in media 
containing 5% serum. Analog of E3330, RN7-58 (grey bars) was also utilized but did not induce NRF2 
activity. *, p < 0.05, ** p < 0.01; #, p < 0.001, comparing drug-treated cells to DMSO vehicle control, 
n=3-5.   
FIGURE 4. Inhibition of Ref-1 induces expression of NRF2 and HMOX-1. A) Patient-derived cells, 
Pa03C and Panc10.05, and PaCa-2 cells show dose-dependent, significant upregulation of NRF2 protein 
levels following treatment with Ref-1 inhibitor but not with RN7-58 (RN, 50 µM). Cells were treated 
with E3330 or RN7-58 for 24 h for PaCa-2 and 5 h for patient lines. *, p < 0.05 versus DMSO control; n 
= 4. B) Similar increases are observed with NRF2 target gene, HMOX-1 following inhibition of Ref-1. 
Cells were treated with E3330 or RN7-58 for 24 h and then collected for immunoblotting. *, p < 0.05 
versus DMSO control; n = 4. Error bars, ± SE 
FIGURE 5. The increase in NRF2 activity is not due to an increase in ROS. Quantitation of ROS by 
DHR-123 fluorescence following inhibition of Ref-1 demonstrates no increase in ROS in either patient 
derived cells or PaCa-2 cells. Cells were treated with E3330 for 24 h and harvested for ROS levels. 
Positive control TBHP shows a significant increase in ROS generation as expected. Error bars, ± SE 
FIGURE 6. NRF2 interacts with Ref-1 in PDAC cells. Cell extracts were prepared from PaCa-2 cells 
that overexpress Ref-1 (A) and had been treated with E3330 for 24 h (A and B). Extracts were 
immunoprecipitated with anti-NRF2 (A) or anti-Ref-1 (B) antibody or IgG.  The immunoprecipitated 
complexes were then probed for NRF2 or Ref-1.  
FIGURE 7.  Ref-1 associates with NRF2 binding sites on HMOX-1 promoter and inhibition of Ref-
1 diminishes this binding. A) Schematic of the NRF2 binding sites on HMOX-1 promoter.(30). B) ChIP 
assay to show Ref-1 is part of a complex on the HMOX-1 promoter and treatment with Ref-1 inhibitor 
can significantly diminish the amount of Ref-1 associated with the HMOX-1 promoter. C) ChIP assay 
with anti-NRF2 antibody demonstrating that there is more NRF2 bound to the chromatin following Ref-1 
inhibition.  However, RN7-58 does not increase the amount of NRF2 bound to the HMOX-1 promoter. D 
and E) Ref-1 siRNA #1 and pooled Ref-1 siRNAs #3 & #4 decrease the amount of NRF2 bound to the 
HMOX1 promoter. MCM5 is included as a negative control to demonstrate that the NRF2 – Ref-1 pull 
down is not due to non-specific chromatin binding. IgG and NTC (no template control) serve as controls 
for the ChIP assay. 
FIGURE 8. Combination treatment of Ref-1 inhibitor and HMOX-1 inhibitor is synergistic under 
hypoxic conditions, but not low glucose. A) PaCa-2 cells were treated with increasing amounts of 
HMOX-1 inhibitor (Sn-PP) in combination with Ref-1 inhibitor E3330(50 or 80 µM) simultaneously 
under several conditions. Top: normal oxygen; Middle panel: 0.2% hypoxia; and bottom panel: low 
glucose. B) Patient derived cells, Pa03C were treated with increasing amounts of E3330 in combination 
with 25 µM Sn-PP and then placed under hypoxic conditions (0.2%). Cell survival was assessed via MTS 
assay 48 h after treatment for both cell lines. Error bars, ± SE 
FIGURE 9. Immunohistochemical staining of HMOX-1 in PDAC patient-derived tissue from live 
PancXenoBank. Mice were treated with either vehicle control (n=7, Cremophor:EtOH (4%) or E3330 
(n=15, 25 mg/kg)) for 2 weeks and tumors harvested following last dose.(4) (p<0.05 using unpaired t test 
with Welch’s correction, one-tailed) 
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TABLE 1. Primers utilized in ChIP assay. 
PRIMER 
NAME 
SEQUENCE 5’ to 3’  HMOX1 
PROMOTER 
LOCATION 
REFERENCE 
E1 for CAGTGCCTCCTCAGCTTCTC -3899 to -3880 (30) 
E1 rev CTCGGTGGATTGCAACATTA -3716 to -3697 (30) 
E2 for TAATCCTTTCCCGAGCCA -9083 to -9065 (30) 
E2 rev GGAACTCTGAGGAAAACAAATC -8941 to -8918 (30) 
MCM5 for AGACCATGCGTCAGGAAA  (30) 
MCM5 rev CTGGCTGGGAAGGAAGTG  (30) 
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Figure 5. 
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